Gilead Sciences Finally Starts Succeeding

Sundry Photography Gilead Sciences (NASDAQ:GILD) has been perhaps one of the most discussed biotech companies as an investment. The company effectively was the first to cure Hepatitis C, capitalizing on an incredibly strong HIV business, before competition hurt its market position substantially. Since then, the company has become known for massive acquisitions that have struggled to pan out. Despite that, it seems like the times are finally changing. The company is building an exciting new oncology business ...